Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.

Objectives: To calculate the clavulanic acid exposure of oral amoxicillin/clavulanic acid dosing regimens, to investigate variability using a population pharmacokinetic model and to explore target attainment using Monte Carlo simulations.Methods: Two groups of healthy male volunteers received amoxic...

Full description

Bibliographic Details
Published in:Journal of Antimicrobial Chemotherapy (JAC) Vol. 73; no. 2; pp. 469 - 477
Main Authors: Mouton, Johan W., De Velde, Femke, De Winter, Brenda C. M., Van Gelder, Teun, Koch, Birgit C. P.
Format: research Journal Article
Published: Oxford University Press / USA Feb2018
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127550260&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 127550260
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03057453
        N5O
      jtl: Journal of Antimicrobial Chemotherapy (JAC)
      issn: 03057453
      maglogo: N
    pubinfo:
      dt: Feb2018
      vid: 73
      iid: 2
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        127550260
        127550260
        NLM29136160
        127550260
        10.1093/jac/dkx376
        NLM29136160
        127550260
      ppf: 469
      ppct: 8
      formats:
      tig:
        atl: Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.
      aug:
        au:
          Mouton, Johan W.
          De Velde, Femke
          De Winter, Brenda C. M.
          Van Gelder, Teun
          Koch, Birgit C. P.
        affil: Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
      sug:
        subj:
          Enzyme Inhibitors Pharmacokinetics
          Enzyme Inhibitors Administration and Dosage
          Systems Analysis
          Blood Chemical Analysis
          Research Subjects
          Adult
          Antibiotics Pharmacokinetics
          Human
          Young Adult
          Antibiotics Administration and Dosage
          Middle Age
          Crossover Design
          Adolescence
          Biological Availability
          Male
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Adolescent: 13-18 years
          Male
      ab: Objectives: To calculate the clavulanic acid exposure of oral amoxicillin/clavulanic acid dosing regimens, to investigate variability using a population pharmacokinetic model and to explore target attainment using Monte Carlo simulations.Methods: Two groups of healthy male volunteers received amoxicillin/clavulanic acid tablets at the start of a standard meal on two separate days 1 week apart. One group (n = 14) received 875/125 mg q12h and 500/125 mg q8h and the other group (n = 15) received 500/125 mg q12h and 250/125 mg q8h. In total, 1479 blood samples were collected until 8-12 h after administration. Concentrations were analysed using non-compartmental (WinNonLin) and population pharmacokinetic (NONMEM) methods.Results: Median Cmax and AUC0-8 were 2.21 mg/L (0.21-4.35) and 4.99 mg·h/L (0.44-8.31), respectively. In 40/58 daily concentration-time profiles, Cmax and AUC0-8 of the morning dose were higher than with later doses. The final population model included a lag time (0.447 h), first-order absorption (3.99 h-1 at 8:00 h, between-subject variability 52.8%, between-occasion variability 48.5%), one distribution compartment (33.0 L, between-subject variability 23.9%) and first-order elimination (24.6 L/h, between-subject variability 26.7%). Bioavailability (fixed at 1 at 8:00 h, between-occasion variability 28.2%) and absorption rate decreased over the day. For 97.5% of the simulated population after 125 mg q12h or q8h, %fT > Ct at 0.5 mg/L was 8.33% (q12h) and 15.2% (q8h), %fT > Ct at 1 mg/L was 0% (q12h + q8h), and fAUC0-24 was 3.61 (q12h) and 5.56 (q8h)  mg·h/L.Conclusions: Clavulanic acid absorption in healthy volunteers is highly variable. Bioavailability and absorption rate decrease over the day. The model developed here may serve to suggest clavulanic acid dosing regimens to optimize efficacy and prevent underdosing.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N